Ultragenyx Rare Disease Voucher Sales Secure $413M for More Potential Pipeline Building
Ultragenyx Pharmaceutical sold two priority review vouchers, each from an FDA approval of a gene therapy. Both therapies came from business deals and proceeds from the voucher sales put Ultragenyx in a better financial position to pursue yet another deal for a rare disease asset. The post…
Sources
- T2Ultragenyx Rare Disease Voucher Sales Secure $413M for More Potential Pipeline BuildingFierce Biotech / Fierce Healthcare / MedCity / GEN